Clinical Trial

Defining the Role of Optical Super-high Magnification Dermoscopy in the Diagnosis of Skin Tumors

Study acronym: OSHMD
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective study aimed at evaluating the diagnostic accuracy (compared to histopathological diagnosis) and clinical utility of optical super-high magnification dermoscopy (OSHMD) in detecting and differentiating skin tumors, including both benign and malignant lesions, particularly in nevi/melanoma and basal cell carcinoma, in patients with suspicious lesions at a magnification of 20x. Additionally, the characteristics of skin lesions will be analyzed using OSHMD, and their distribution in skin tumors will be assessed. The agreement between the examiners' evaluations and the concordance between dermoscopic diagnoses at 20x and 400x compared to histopathological diagnosis will also be examined. The hypothesis is that OSHMD could assist in identifying malignancy features, thus improving the diagnostic accuracy of skin tumors and potentially leading to earlier and more precise detection of neoplasms
Trial Details
NCT Number NCT06908720
Lead Sponsor IRCCS Ospedale San Raffaele
Conditions Skin Cancers
Enrollment 1,000 participants
Start Date 2025-04
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-04-03